Short Description Juvena Therapeutics CEO decoding secretomes for tissue rejuvenation.
Description Carnegie Mellon alumna Hanadie Yousef integrates high‑content screening and machine learning to map embryonic secreted proteins that activate regenerative pathways. Juvena’s lead asset JUV‑161 targets muscle stem‑cell decline and received FDA orphan‑drug status for myotonic dystrophy. Yousef mentors women of color in biotech and appears on Forbes Next 1000 lists.